Home Podcasts Base by Base
Base by Base

Base by Base

Gustavo Barra 446 Episodes Sep 13, 2026

Base by Base explores advances in genetics and genomics, focusing on gene-disease associations, variant interpretation, protein structure, and exome and genome sequencing. Each episode breaks down key studies and their clinical relevance one base at a time. The show is AI-powered, offering a new way to learn on the go, and thanks authors who publish under CC BY 4.0 for open-access science.

Episodes

459: Cerebral palsy genetics: 515 candidate genes, evidence for 89
459: Cerebral palsy genetics: 515 candidate genes, evidence for 89 Sep 13, 2026 00:24:06 Arterbery et al., The American Journal of Human Genetics - Hundreds of genes have been reported as causes of cerebral palsy, yet there is no agreed model of what a pathogenic variant in a child with CP actually means. This study treats CP as a phenotypic feature that some genetic disorders make more likely, tests the reported genes against the populatio
458: Somatic or inherited? Reading TP53 risk from shared DNA
458: Somatic or inherited? Reading TP53 risk from shared DNA Sep 10, 2026 00:25:09 MacGregor et al., The American Journal of Human Genetics - Pathogenic TP53 variants found in blood have long been read as inherited Li-Fraumeni alleles, but many turn out to be somatic clones that grew with age. Using whole-exome data from 469,391 UK Biobank participants, this study combines variant allele fraction with haplotype sharing to tell the two
457: A deletion that raises Alzheimer risk, a duplication that lowers it
457: A deletion that raises Alzheimer risk, a duplication that lowers it Sep 9, 2026 00:24:15 Quenez O et al., The American Journal of Human Genetics - Rare copy-number variants were called from 22,319 exomes covering early-onset Alzheimer disease, late-onset disease and unaffected controls, then tested gene by gene for a dosage effect. One locus came back with the cleanest signal in the field: at the central 22q11.21 region, deletions appeared
456: Beyond exons: where heritability hides as traits get more polygenic
456: Beyond exons: where heritability hides as traits get more polygenic Sep 8, 2026 00:45:46 Fuhrer J et al., The American Journal of Human Genetics - Across 34 complex traits and disorders, a MiXeR-based framework partitions SNP heritability over 74 functional annotations and finds that exons carry only a minority of it, and steadily less as a trait becomes more polygenic. Exonic heritability falls from about 22 percent in less-polygenic somat
455: Agentic genomics: the bottleneck moves from code to judgment
455: Agentic genomics: the bottleneck moves from code to judgment Sep 7, 2026 00:13:44 Corpas M et al., Cell Genomics - A Perspective arguing that autonomous AI agents which discover, configure and chain bioinformatics operations from natural-language instructions have shifted the bottleneck in computational biology from building pipelines to validating their output. The authors define four necessary conditions for a system to count as ag
454: Efavirenz retarda a doença priônica mexendo no colesterol do cérebro [PT]
454: Efavirenz retarda a doença priônica mexendo no colesterol do cérebro [PT] Sep 2, 2026 00:17:13 Ali T et al., JCI Insight - Um antirretroviral aprovado para HIV, dado por via oral em microdose, prolongou a sobrevida de camundongos que carregam a proteína priônica humana e foram infectados com príons de doença de Creutzfeldt-Jakob esporádica humana. O efavirenz age ativando a CYP46A1, a enzima cerebral que converte colesterol numa forma capaz de sa
453: Efavirenz slows sCJD progression by reshaping brain cholesterol
453: Efavirenz slows sCJD progression by reshaping brain cholesterol Aug 31, 2026 00:20:56 Ali T et al., JCI Insight - Repurposed low-dose efavirenz slowed disease progression and extended survival in tg650 mice inoculated with MM1 sCJD prions by activating CYP46A1, raising 24S‑hydroxycholesterol and reducing PrPSc, brain cholesterol and lipid droplets at the early clinical stage. Key terms: efavirenz, CYP46A1, Creutzfeldt-Jakob disease, chol
452: Reduzir a PrP funciona em todas as linhagens [PT]
452: Reduzir a PrP funciona em todas as linhagens [PT] Aug 28, 2026 00:28:42 Minikel EV et al., Nucleic Acids Research - Este estudo testa a redução da proteína priônica (PrP) por oligonucleotídeos antisense (ASOs) em camundongos, variando doses, esquemas de aplicação, linhagens de príon e estágios da doença. O tratamento reduziu o RNA do Prnp, prolongou a sobrevida, atrasou os sintomas e reverteu biomarcadores de lesão neuronal
451: Prion protein lowering is disease-modifying across stages and strains
451: Prion protein lowering is disease-modifying across stages and strains Aug 25, 2026 00:24:36 Minikel EV et al., Nucleic Acids Research - This study uses antisense oligonucleotides (ASOs) to lower prion protein (PrP) RNA in mice and shows dose-dependent extension of survival, efficacy across multiple prion strains, reversal of molecular biomarkers, and benefit even when treatment is delayed into symptomatic stages. Key terms: prion protein, anti
450: ASOs que reduzem PrP prolongam a sobrevida [PT]
450: ASOs que reduzem PrP prolongam a sobrevida [PT] Aug 24, 2026 00:24:57 Raymond GJ et al., JCI Insight - This episode covers a 2019 study showing that sequence-specific antisense oligonucleotides (ASOs) targeting the prion protein (PrP) mRNA, delivered by bolus intracerebroventricular injection, lower PrP levels in the CNS, slow neuropathology, and markedly extend survival in prion-infected wild-type mice when given prophyl
449: siRNA divalente para doença priônica [PT]
449: siRNA divalente para doença priônica [PT] Aug 24, 2026 00:28:46 Gentile JE et al., Nucleic Acids Research - Discovery and preclinical development of divalent siRNA candidates targeting PRNP, identifying 2439-s4 as a potent, durable human PRNP-lowering drug candidate with IND clearance. Key terms: prion disease, PrP lowering, divalent siRNA, 2439-s4, RNAi therapeutics. Study Highlights:Authors screened divalent siRN
448: PrP‑lowering ASOs prolong survival in prion‑infected mice
448: PrP‑lowering ASOs prolong survival in prion‑infected mice Aug 23, 2026 00:25:16 Raymond GJ et al., JCI Insight - This study tests antisense oligonucleotides (ASOs) targeting Prnp in wild‑type mice infected with RML prions and shows that sequence‑specific PrP lowering by bolus i.c.v. ASO dosing delays disease and extends survival, even when given near clinical onset. Key terms: prion disease, antisense oligonucleotide, PrP lowering,

Recommended